Natixis Advisors LLC Purchases 110,826 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Key Points

• Natixis Advisors LLC increased its stake in Bristol Myers Squibb by 16.3% during the first quarter, holding a total of 791,667 shares worth approximately $48.28 million.
• Bristol Myers Squibb reported an earnings per share (EPS) of $1.46 for the last quarter, exceeding analysts' expectations of $1.07 and achieving a revenue of $12.27 billion.
• The company announced a quarterly dividend of $0.62 to be paid on August 1st, representing a 5.7% yield and a payout ratio of 92.88%.

Natixis Advisors LLC grew its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 16.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 791,667 shares of the biopharmaceutical company's stock after purchasing an additional 110,826 shares during the quarter. Natixis Advisors LLC's holdings in Bristol Myers Squibb were worth $48,284,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the company. Thoroughbred Financial Services LLC lifted its holdings in shares of Bristol Myers Squibb by 1.1% in the fourth quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company's stock worth $1,004,000 after buying an additional 190 shares in the last quarter. Marcum Wealth LLC lifted its holdings in shares of Bristol Myers Squibb by 1.0% in the first quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock worth $1,177,000 after buying an additional 193 shares in the last quarter. Beacon Investment Advisory Services Inc. lifted its holdings in shares of Bristol Myers Squibb by 2.7% in the first quarter. Beacon Investment Advisory Services Inc. now owns 8,063 shares of the biopharmaceutical company's stock worth $492,000 after buying an additional 212 shares in the last quarter. 1858 Wealth Management LLC lifted its holdings in shares of Bristol Myers Squibb by 3.6% in the first quarter. 1858 Wealth Management LLC now owns 6,421 shares of the biopharmaceutical company's stock worth $392,000 after buying an additional 221 shares in the last quarter. Finally, Tompkins Financial Corp lifted its holdings in shares of Bristol Myers Squibb by 2.5% in the first quarter. Tompkins Financial Corp now owns 9,151 shares of the biopharmaceutical company's stock worth $558,000 after buying an additional 225 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on BMY. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 target price (down previously from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. Citigroup decreased their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research note on Friday. William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Argus raised shares of Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 price target on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, fourteen have given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $56.38.

Bristol Myers Squibb Trading Up 0.5%

Shares of NYSE BMY traded up $0.24 during mid-day trading on Tuesday, reaching $45.64. The company had a trading volume of 6,169,117 shares, compared to its average volume of 13,511,545. The business's 50-day moving average is $47.48 and its 200-day moving average is $52.15. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The stock has a market cap of $92.87 billion, a price-to-earnings ratio of 18.41, a price-to-earnings-growth ratio of 2.33 and a beta of 0.36. Bristol Myers Squibb Company has a 52 week low of $42.96 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion for the quarter, compared to analysts' expectations of $11.32 billion. During the same period in the prior year, the business earned $2.07 EPS. The firm's quarterly revenue was up .6% on a year-over-year basis. Equities analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.4%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is presently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.